Shares of multinational healthcare giant Johnson & Johnson (NYSE: JNJ) closed nearly 3% higher on Tuesday despite the company’s fourth-quarter sales results falling short of expectations. Adjusted EPS increased 14.5% year-over-year to $2.13, coming in just above the Street’s estimate of $2.12. Sales grew 10.4% year-over-year to $24.8 billion, missing analyst expectations of $25.29 billion.   The Consumer Health segment’s sales rose 1.1% to $3.7 billion, Pharmaceutical segment sales jumped 16.5% to $14.3 billion, and the Medical Devices segment’s sales climbed 4.1% to $6.9 billion. JNJ CEO Joaquin Duato said, “Given our strong results, financial profile, and innovative pipeline we are well-positioned for success in 2022 and beyond.
https://www.tipranks.com/news/j-j-gains-3-despite-quarterly-sales-miss?utm_source=advfn.com&utm_medium=referral
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Johnson and Johnson Charts.